Table 1.
Characteristics of patients treated on E2603 included in this analysis
| n = 115 | |
|---|---|
| Characteristic | n (%) |
| Male sex | 77 (67.0) |
| Median age, years (range) | 59 (23–82) |
| AJCC stage | |
| Unresectable stage III | 16 (13.9) |
| M1a/M1b | 41 (35.7) |
| M1c | 58 (50.4) |
| Serum LDH at baseline | |
| Normal | 65 (56.5) |
| Above normal | 47 (40.9) |
| ECOG performance status | |
| 0 | 67 (58.3) |
| 1 | 48 (41.7) |
| Prior systemic therapy | |
| None | 52 (45.2) |
| Interferon, IL-2, GM-CSF | 59 (51.3) |
| Investigational therapy | 4 (3.5) |
| Treatment arm | |
| Carboplatin/paclitaxel | 58 (50.4) |
| Carboplatin/paclitaxel/sorafenib | 57 (49.6) |
| BRAF status | |
| Mutant | 48 (41.8) |
| V600E | 34 (29.6) |
| V600K | 8 (7.0) |
| V600R | 3 (2.6) |
| V600D | 1 (0.9) |
| K601E | 2 (1.7) |
| Wild-type | 52 (45.2) |
| Unknown | 15 (13.0) |
| NRAS status | |
| Mutant | 22 (19.1) |
| G13R | 2 (1.7) |
| G13C | 1 (0.9) |
| Q61R | 9 (7.8) |
| Q61K | 8 (7.0) |
| D61L | 2 (1.7) |
| Wild-type | 78 (67.8) |
| Unknown | 15 (13.0) |
| Survival | |
| Median OS, months (range) | 9.8 (0.5–56.9) |
| Median PFS, months (range) | 4.4 (0.5–42.1) |